Abstract:Objective To explore the clinical effect of Pemetrexed combined with Shenqi Fuzheng Injection as first line treatment in elderly patients with advanced lung adenocarcinoma.Methods A total of 80 cases of elderly patients with advanced lung adenocarcinoma treated in our hospital from February 2016 to October 2017 were selected as subjects.They were randomly divided into the control group and the observation group with 40 cases in each group,according to the random number table method.The control group was treated with Pemetrexed alone,and the observation group was combined with Shenqi Fuzheng Injection on the basis of chemotherapy in the control group.The total effective rate,the tumor control rate,the incidence of adverse reaction,the sleep quality score and life quality score before and after treatment were compared.Results There were no statistically significant differences in total effective rate and tumor control rate between two groups(P>0.05).The incidence of adverse reactions in the observation group(2.50%)was lower than that of the control group (27.50%),and the difference was statistically significant(P<0.05).Before treatment,the scores of sleep quality and life quality in two groups had no statistically significant differences(P>0.05).After treatment,the score of sleep quality in the observation group was lower than that of the control group,the score of life quality was higher than that of the control group,and the differences between the groups were statistically significant(P<0.05).Conclusion Pemetrexed combined with Shenqi Fuzheng Injection has some effect in the treatment of elderly patients with advanced lung adenocarcinoma,while combined treatment can effectively reduce the incidence of adverse reactions and significantly improve the prognosis of patients,which is worthy of clinical application.
詹勤元;蔡云;陈颖兰. 培美曲塞联合参芪扶正注射液一线治疗老年晚期肺腺癌的效果[J]. 中国当代医药, 2018, 25(20): 131-133.
ZHAN Qin-yuan;CAI Yun;CHEN Ying-lan. Effect of Pemetrexed combined with Shenqi Fuzheng Injection as first line treatment in elderly patients with advanced lung adenocarcinoma. 中国当代医药, 2018, 25(20): 131-133.